Eyenovia announced that the Company has commenced manufacturing of registration batches of its FDA-approved mydriasis product, Mydcombi, a key step in the approval process for its Gen-2 Optejet dispensing platform. Mydcombi will undergo 12-month stability testing and other functional testing in the Gen-2 Optejet device that is consistent with feedback from the Type-C meeting on Eyenovia’s device qualification plan that the Company received from the FDA in July. Eyenovia anticipates completion of testing of its Mydcombi registration batches by the end of next year, with a potential SNDA filing in early 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYEN:
- Eyenovia Announces Share Offering and Warrant Sale for Growth
- Eyenovia to sell 8.7M shares at 46c in registered direct offering
- Eyenovia announces launch, commercial availability of Clobetasol
- Eyenovia announces Formosa granted Taiwan Export License
- Eyenovia Announces CFO Transition and New Financial Leadership